The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Timeframe: From Day 1 of dosing maximum up to Week 68
Number of Participants With Laboratory Abnormalities
Timeframe: From Day 1 of dosing maximum up to Week 68
Number of Participants According to Categorization of Changes in Vital Signs
Timeframe: From Day 1 of dosing maximum up to Week 68
Number of Participants According to Categorization of Electrocardiogram (ECG) Findings
Timeframe: From Day 1 of dosing maximum up to Week 68